Strata Skin Sciences Faces Nasdaq Listing Requirements Woes

Strategic Insights -

Strata Skin Sciences, Inc., a leading provider of innovative dermatology and aesthetic solutions, has been grappling with compliance issues related to Nasdaq listing requirements. On August 22, 2025, the Company received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") advising that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000. In response, the Company submitted a plan to regain compliance with the stockholders' equity requirement on September 19, 2025. Nasdaq accepted the plan and granted the Company an extension until February 16, 2026, to regain compliance.

Key Takeaways:

  • Strata Skin Sciences, Inc. received a deficiency notification letter from Nasdaq on August 22, 2025, indicating that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market.
  • The Company submitted a plan to regain compliance with the stockholders' equity requirement on September 19, 2025, which was accepted by Nasdaq on October 13, 2025.
  • The Company has been granted an extension until February 16, 2026, to regain compliance with the stockholders' equity requirement.
  • Failure to regain compliance by February 16, 2026, could result in delisting of the Company's common stock.
  • The Company is currently evaluating various courses of action to regain compliance, but there can be no assurance that it will be able to do so.

Statistics:

  • Minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market: at least $2,500,000 (Nasdaq Listing Rule 5550(b)(1))
  • Date of deficiency notification letter from Nasdaq: August 22, 2025
  • Date of plan submission to regain compliance: September 19, 2025
  • Date of plan acceptance by Nasdaq: October 13, 2025
  • Date of compliance extension: October 13, 2025
  • Deadline for regaining compliance: February 16, 2026

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2025